Download
00296_2024_Article_5581.pdf 1,10MB
WeightNameValue
1000 Titel
  • Evaluation of a hybrid telehealth care pathway for patients with axial spondyloarthritis including self-sampling at home: results of a longitudinal proof-of-concept mixed-methods study (TeleSpactive)
1000 Autor/in
  1. Labinsky, Hannah |
  2. May, Susann |
  3. Boy, Katharina |
  4. von Rohr, Sophie |
  5. Grahammer, Manuel |
  6. Kuhn, Sebastian |
  7. Rojas, Jessica |
  8. (Eimer) Vogt, Ekaterina |
  9. Heinze, Martin |
  10. Schett, Georg |
  11. Muehlensiepen, Felix |
  12. Knitza, Johannes |
1000 Verlag
  • Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-04-11
1000 Erschienen in
1000 Quellenangabe
  • 44(6):1133-1142
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00296-024-05581-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11108867/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Patients with axial spondyloarthritis (axSpA) require close monitoring to achieve the goal of sustained disease remission. Telehealth can facilitate continuous care while relieving scarce healthcare resources. In a mixed-methods proof-of-concept study, we investigated a hybrid telehealth care axSpA pathway in patients with stable disease over 6 months. Patients used a medical app to document disease activity (BASDAI and PtGA bi-weekly, flare questionnaire weekly). To enable a remote ASDAS-CRP (TELE-ASDAS-CRP), patients used a capillary self-sampling device at home. Monitoring results were discussed and a decision was reached via shared decision-making whether a pre-planned 3-month on-site appointment (T3) was necessary. Ten patients completed the study, and eight patients also completed additional telephone interviews. Questionnaire adherence was high; BASDAI (82.3%), flares (74.8%) and all patients successfully completed the TELE-ASDAS-CRP for the T3 evaluation. At T3, 9/10 patients were in remission or low disease activity and all patients declined the offer of an optional T3 on-site appointment. Patient acceptance of all study components was high with a net promoter score (NPS) of +50% (mean NPS 8.8 ± 1.5) for self-sampling, +70% (mean NPS 9.0 ± 1.6) for the electronic questionnaires and +90% for the T3 teleconsultation (mean NPS 9.7 ± 0.6). In interviews, patients reported benefits such as a better overview of their condition, ease of use of telehealth tools, greater autonomy, and, most importantly, travel time savings. To our knowledge, this is the first study to investigate a hybrid approach to follow-up axSpA patients including self-sampling. The positive results observed in this scalable proof-of-concept study warrant a larger confirmatory study.</jats:p>
1000 Sacherschließung
lokal Surveys and Questionnaires [MeSH]
lokal Telemedicine [MeSH]
lokal Female [MeSH]
lokal Self Care/methods [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Longitudinal Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Surveys and questionnaires
lokal Axial spondyloarthritis
lokal axSpA
lokal Male [MeSH]
lokal Axial Spondyloarthritis/therapy [MeSH]
lokal Electronic patient-reported outcome
lokal Treat-to-target
lokal ePRO
lokal Patient Opinion
lokal Mobile Applications [MeSH]
lokal Proof of Concept Study [MeSH]
lokal Axial Spondyloarthritis/diagnosis [MeSH]
lokal Shared decision-making
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-5762-9182|https://orcid.org/0000-0003-3847-4861|https://orcid.org/0009-0009-9616-6278|https://orcid.org/0009-0005-1509-266X|https://orcid.org/0000-0003-1560-4459|https://orcid.org/0000-0002-8031-2973|https://orcid.org/0000-0002-5578-8160|https://orcid.org/0000-0002-6942-1714|https://orcid.org/0000-0003-3645-1033|https://orcid.org/0000-0001-8740-9615|https://orcid.org/0000-0001-8571-7286|https://orcid.org/0000-0001-9695-0657
1000 Hinweis
  • DeepGreen-ID: fa181d974c4d4bb091ba52a05460de2d ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Deutsche Forschungsgemeinschaft |
  2. Novartis Pharma |
  3. Universitätsklinikum Würzburg |
1000 Fördernummer
  1. -
  2. -
  3. -
1000 Förderprogramm
  1. -
  2. -
  3. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Deutsche Forschungsgemeinschaft |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Novartis Pharma |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Würzburg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6491754.rdf
1000 Erstellt am 2025-02-03T15:30:51.896+0100
1000 Erstellt von 322
1000 beschreibt frl:6491754
1000 Zuletzt bearbeitet 2025-07-30T10:43:37.953+0200
1000 Objekt bearb. Wed Jul 30 10:43:37 CEST 2025
1000 Vgl. frl:6491754
1000 Oai Id
  1. oai:frl.publisso.de:frl:6491754 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source